Overview

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary Objective of this study is to evaluate the safety and tolerability of intraocular injections of 0.5mg or 2.0mg of ranibizumab in patients with macular edema due to retinal vein occlusion.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peter A Campochiaro, MD
Collaborator:
Genentech, Inc.
Treatments:
Ranibizumab